Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 4, 2006, Pages 384-389

  Leong, Anthony S Y ^a   Formby, Mark ^a   Haffajee, Zenobia ^a   Clarke, Megan ^a   Morey, Adrienne ^b  

^a JOHN HUNTER HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Breast cancer; FISH; Her2 neu; Immunohistochemistry

Indexed keywords

ANATOMY; ARTICLE; BREAST CANCER; CELL MEMBRANE; CHROMOGENIC IN SITU HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; INTERMETHOD COMPARISON; ONCOGENE NEU; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING TEST; TUMOR CELL; VALIDATION PROCESS;

BREAST NEOPLASMS; CELL MEMBRANE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 33748954579     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000210415.53493.d4     Document Type: Article

References (24)

1. Check W. IHC, FISH still sharing Her2/neu spotlight. CAP Today. 2005;19:37.
2. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of Her2/neuoverexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
3. Yardley DA, Hainsworth JD, Greco FA, et al. Preserved chemosensitivity to weekly paclitaxel and carboplatinum Her2/neu+ patients irrespective of response to first-line intensified induction Herceptin single agent. Paper presented at the Annual Meeting of the American Society of Clinical Oncology; May 18 to 21, 2002, Orlando, FL. Abstract No.12.
4. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol. 2000;113:171-175.
5. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin. 1999;17:1983-1987.
6. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;271:1972-1977.
7. Acs G, Wang L, Raghunath PN, et al. Role for different immunostaining patterns in HercepTest interpretation and criteria for gene amplification as determined by fluorescence in situ hybridisation. Appl Immunohistochem Mol Morphol. 2003;11:222-229.
8. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Concensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
9. Miller K. The breast HER-2 module. Immunocytochemistry (UKNEQAS). 2004;3:96-99.
10. De Potter CR, Quatacker J, Maertens G, et al. The subcellular localisation of the neu protein in human normal and neoplastic cells. Int J Cancer. 1989;44:969-974.
11. Rohan TE, Harwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-cerbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Canc Inst. 1998;90:1262-1269.
12. Mottolese M, Nadasi EA, Botti C, Cianciulli AM, et al. Phenotypic changes of p53, HER2/NEU, and Fas system in multiple normal tissues surrounding breast cancer. J Cell Physiol. 2005;204:106-112.
13. DakoCytomation. HercepTest™ Product Insert. 5th ed. 2003:16.
14. Bilous M. Her2/neu testing recommendations in Australia. Pathology. 2001;33:425-427.
15. Leong AS-Y. Editorial: Quantitation in immunohistology - Fact or Fiction? A discussion of factors that influence results. Appl Immunohistochem Mol Morphol. 2004;12:1-7.
16. Hanna W, Kahn HJ, Andrulis I, Pawson T. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases. Mod Pathol. 1990;3:455-461.
17. Leong AS-Y, Leong TY-M. Recent developments in immunohistology. J Clin Pathol. In press.
18. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of Her2/neu in breast cancer: results of the French Multicentre GEFPICS Study. Histopathology. 2003;42:337-347.
19. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777
20. Leong AS-Y. Pitfalls in diagnostic immunohistology. Adv Anat Pathol. 2004;11:86-93.
21. Lehr HA, Jacobs TW, Yaziji H, et al. Quantitative evaluation of HER-2/neu status in breast cancers by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol. 2001;115:814-822.
22. Jacobs TW, Gown AM, Yaziji H, et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol. 2000;113:251-258.
23. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable Her2/neu-positive breast cancer. New Engl J Med. 2005;353:1673-1684.
24. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2/neu-positive breast cancer. New Engl J Med. 2005;353:1659-1672.